Document is current

Article History

Received: 12 March 2025

Revised: 26 April 2025

Accepted: 28 April 2025

First Online: 14 May 2025

Declarations

:

: VDS received compensation for speaking from Alexion, UCB, Argenx and Alnylam; he is Sub-Investigator in clinical trials for Alexion, Alnylam, Argenx, Dianthus, and Sanofi. RI received speaker honoraria and consultancy fees from Alexion, Aera Therapeutics, Amgen, Argenx, Dianthus Therapeutics, Johnson&Johnson, Merck, and UCB. FH received speaker honoraria and consultancy fees from Argx, UCB, Alexion, Johnson Johnson MM received speaker honoraria and consultancy fees from Alexion, Argenx, UCB. CV has received honoraria for speakers, manuscript writing, educational events and support for attending meetings and travels from Alexion, ArgenX, UCB, and Sanofi. EMP received speaker honoraria and consultancy fees from Alexion, Argenx, UCB, Sanofi. DR has received honoraria for speakers, educational events and support for attending meeting and travels from Alexiox, UCB, Argenx and CSL Behring. SM received public speaking honoraria and travel grants from Alexion; MG received speaker honoraria and consultancy fees from Sanofi, Dianthus, Kedrion. LL received speaker honoraria and consultancy fees from Argx. GA received conference honoraria, advisory board and travel grants from Kedrion, Alnylam, Alexion, Argenx, Takeda; LF received public speaking honoraria and/or Advisory boards and travel grants from Alexion, Argenx, UCB, Dianthus. All the other authors reported no disclosures.

: Written informed consent was obtained from the patient for the publication of anonymized data. We confirm that this work is in line with journal’s position on issues involved in ethical publication.